Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1715830

	registered interest
	date	03/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Hormones: Sales
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with the Medicines and Healthcare products Regulatory Agency on steps to (a) tackle the illegal sale of cross-sex hormones online and (b) protect public health.
	tabling member constituency	Slough
	tabling member printed	Mr Tanmanjeet Singh Dhesi
	uin	24802
	answer	answer is ministerial correction date of answer 09/05/2024 answer text <p>Strict regulatory controls govern medicinal products for human use, including their manufacture, distribution, retail sale and supply, and advertisement. The medicines referred to cannot be advertised directly to the public, and any online offer to sell or supply them to a patient would likely contravene the Human Medicines Regulations 2012.</p><p>Instances of United Kingdom-based non-compliant activity relating to the online advertising, sale, or supply of medicines are reviewed by the Medicines and Healthcare products Regulatory Agency (MHRA) on a case-by-case basis, and appropriate action taken. Enforcement options include removal of the offending weblink, remedial intervention to bring the owner into compliance, or a criminal investigation and possible prosecution.</p><p>The MHRA also works closely with partners to prevent medicines from entering or being traded in the UK illegally. The MHRA’s Fake Meds campaign encourages people in the UK to use safe and legitimate sources when buying medication online. The MHRA also promotes the reporting of suspicious medicinal products and adverse side effects via its Yellow Card scheme. Further information on the Fake Meds campaign and the Yellow Card scheme is available, respectively, at the following links:</p><p><a href="https://fakemeds.campaign.gov.uk/" target="_blank">https://fakemeds.campaign.gov.uk/</a></p><p><a href="https://yellowcard.mhra.gov.uk/" target="_blank">https://yellowcard.mhra.gov.uk/</a></p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 09/05/2024 13:10:41 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1715833

	registered interest
	date	03/05/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescription Drugs: Sales
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he plans to bring forward legislative proposals to tackle the online sale of prescription-only medications without a prescription.
	tabling member constituency	Slough
	tabling member printed	Mr Tanmanjeet Singh Dhesi
	uin	24803
	answer	answer is ministerial correction date of answer 14/05/2024 answer text <p>The sale and supply of prescription-only medicines is regulated by the Human Medicines Regulations 2012 (HMR). The HMR provides inspection and enforcement powers for the Medicines and Healthcare products Regulatory Agency, and creates criminal offences in respect of non-compliance with those regulations. At this time, the Department has no plans to legislate the online sale of prescription-only medicines without a prescription.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 14/05/2024 16:37:59 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1702405

	registered interest
	date	19/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Clinical Trials: Children
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure (a) transparency and (b) parental consent in clinical trials involving children.
	tabling member constituency	Slough
	tabling member printed	Mr Tanmanjeet Singh Dhesi
	uin	22789
	answer	answer is ministerial correction date of answer 24/04/2024 answer text <p>There are legal measures in place to ensure informed consent in clinical trials, through the Medicines for Human Use (Clinical Trials) Regulations 2004. Parental consent for clinical trials investigating medicines which involve children is also legislated for via the same Regulations.</p><p>Promoting and ensuring transparency is central to the role of the Health Research Authority to facilitate safe and ethical research as defined in the Care Act 2014. This includes clinical trials involving children.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 22790 question first answered 24/04/2024 16:22:38 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1702406

	registered interest
	date	19/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Clinical Trials
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what measures are in place to ensure informed consent in clinical trials.
	tabling member constituency	Slough
	tabling member printed	Mr Tanmanjeet Singh Dhesi
	uin	22790
	answer	answer is ministerial correction date of answer 24/04/2024 answer text <p>There are legal measures in place to ensure informed consent in clinical trials, through the Medicines for Human Use (Clinical Trials) Regulations 2004. Parental consent for clinical trials investigating medicines which involve children is also legislated for via the same Regulations.</p><p>Promoting and ensuring transparency is central to the role of the Health Research Authority to facilitate safe and ethical research as defined in the Care Act 2014. This includes clinical trials involving children.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 22789 question first answered 24/04/2024 16:22:38 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1702197

	registered interest
	date	18/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Strikes (Minimum Service Levels) Act 2023
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment her Department has made of the impact of the Strikes (Minimum Service Levels) Act 2023 on the ability of healthcare professionals to participate in industrial action.
	tabling member constituency	Slough
	tabling member printed	Mr Tanmanjeet Singh Dhesi
	uin	22623
	answer	answer is ministerial correction date of answer 23/04/2024 answer text <p>The Strikes (Minimum Service Levels) Act 2023 allows for regulations to be laid in Parliament in the health sector. The Strikes (Minimum Service Levels: NHS Ambulance Services and the NHS Patient Transport Service) Regulations 2023 came into force on 8 December 2023.</p><p>As we set out in in our consultation response on minimum service levels in the ambulance sector, in our engagement with representatives from ambulance trusts, they indicated that establishing a minimum service level at the level specified in the regulations would require approximately 80% of an ambulance service’s resources on a typical shift. Therefore, if an employer chose to issue work notices during a strike, it is likely that a high proportion of all levels of paramedics, emergency care assistants, and other staff in the ambulance teams rostered to work on a strike would be named, and this would have a significant impact on the ability of employees to participate in strike action. The Department has consulted on whether to implement similar regulations for hospital services, and will set out its response in due course.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 23/04/2024 13:48:18 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1702199

	registered interest
	date	18/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Strikes
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions she has had with healthcare professionals on minimum service levels during strikes in the NHS.
	tabling member constituency	Slough
	tabling member printed	Mr Tanmanjeet Singh Dhesi
	uin	22625
	answer	answer is ministerial correction date of answer 23/04/2024 answer text <p>As part of the consultations on introducing minimum service levels in both ambulance and hospital services, the Department hosted workshops to which a wide range of representative groups were invited. This included employer and provider organisations, and unions representing healthcare professionals.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 23/04/2024 13:50:34 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1699131

	registered interest
	date	26/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Whooping Cough: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she is taking steps to ensure adequate supplies of pertussis vaccine in the context of the rise in instances in the Czech Republic.
	tabling member constituency	Slough
	tabling member printed	Mr Tanmanjeet Singh Dhesi
	uin	20743
	answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>The UK Health Security Agency (UKHSA) centrally procures and manages the United Kingdom’s supply of the pertussis vaccine, for the routine national immunisation programmes. Due to the stockpiles maintained in the UK for the national programme, there is good supply available of all pertussis-containing vaccines for the routine immunisation programmes.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 15/04/2024 08:47:34 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1697900

	registered interest
	date	21/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Ovarian Cancer: Diagnosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether her Department plans to shorten the diagnostic pathway for ovarian cancer by allowing the CA125 blood test and ultrasound to be undertaken at the same time.
	tabling member constituency	Slough
	tabling member printed	Mr Tanmanjeet Singh Dhesi
	uin	19930
	answer	answer is ministerial correction date of answer 02/04/2024 answer text <p>The Department is supporting NHS England in developing Best Practice Timed pathways, to support the ongoing improvement effort to shorten diagnosis pathways, reduce variation, improve patient experience of care, and meet the Faster Diagnosis Standard. This standard ensures patients are told they have cancer, or that cancer is ruled out, within 28 days of urgent cancer referral from general practice or screening service.</p><p>In March 2023, NHS England published guidance for local health and care systems to implement a timed gynaecological cancer diagnostic pathway, including for ovarian cancer. The gynaecological pathway ensures that at day zero, when presenting with symptoms, an ultrasound and a minimum data set is obtained, which includes a full blood count. For patients with suspected ovarian cancer, the minimum dataset should also include tumour marker CA125, with confirmation of suspicious features of ovarian cancer on ultrasound.</p><p>The guidance further ensures that patients with persistent abdominal symptoms, raised CA125, and a normal pelvic scan should be referred through the non-specific symptoms rapid diagnostic centre pathway. Women over 50 years old with elevated CA125 and palpable mass or ascites, or both, or with a previous ultrasound with risk of malignancy, should be referred straight to a computed tomography scan.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 02/04/2024 15:37:44 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1697901

	registered interest
	date	21/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Ovarian Cancer: Diagnosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to reduce regional variations in early diagnosis of ovarian cancer.
	tabling member constituency	Slough
	tabling member printed	Mr Tanmanjeet Singh Dhesi
	uin	19931
	answer	answer is ministerial correction date of answer 28/03/2024 answer text <p>Reducing inequalities and variation in cancer treatment is a priority for the Government, as is increasing early cancer diagnosis, as both are key contributors to reducing cancer health inequalities. The National Health Service is improving cancer pathways to get people diagnosed faster once referred, and is looking into alternative routes into the system, including non-specific symptom (NSS) pathways for patients who do not fit clearly into a single urgent cancer referral pathway, but who are at risk of being diagnosed with cancer. This will help support faster ovarian cancer diagnosis. 113 NSS pathways are currently operational, with more in development.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 28/03/2024 11:38:14 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1696676

	registered interest
	date	18/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the adequacy of (a) funding and (b) support available for research into non-invasive cancer monitoring technologies.
	tabling member constituency	Slough
	tabling member printed	Mr Tanmanjeet Singh Dhesi
	uin	19142
	answer	answer is ministerial correction date of answer 26/03/2024 answer text <p>Research is crucial in tackling cancer, which is why the Department invests over £1 billion per year in health research through the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was £121.8 million in 2022/23 and the NIHR spends more on cancer than any other disease group.</p><p>In terms of adequacy of funding, the NIHR funds research in response to proposals received from scientists, rather than allocating funding to specific disease areas. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.</p><p> </p><p>Regarding technologies, the NIHR’s Invention for Innovation (i4i) Programme is a translational research funding scheme aimed at supporting medical devices, such as non-invasive cancer monitoring technologies, and includes in vitro diagnostic devices and digital health technologies addressing an existing or emerging health or social care need. Further information is available at the following link:</p><p><a href="https://www.nihr.ac.uk/explore-nihr/funding-programmes/invention-for-innovation.htm" target="_blank">https://www.nihr.ac.uk/explore-nihr/funding-programmes/invention-for-innovation.htm</a></p><p>Additionally, in September 2023, the Office for Life Sciences Cancer Mission launched the £12 million NIHR i4i Cancer Mission: Early Cancer Diagnosis Clinical Validation and Evaluation Call, aiming to support the clinical validation and evaluation of breakthrough technologies that can increase the proportion of cancers that are detected earlier in the disease course and target health inequalities in cancer diagnosis.</p><p>The NIHR continues to welcome and encourage funding applications for research into any aspect of human health, including cancer monitoring technologies, and it is worth noting that all applications that were fundable in open competition, have been funded.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 26/03/2024 12:01:10 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi